Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab [10]

British Journal of Dermatology

Volumn 150, Issue 4, 2004, Pages 784-786

  Bartke, U ^a   Venten, I ^a   Kreuter, A ^a   Gabbay, S ^a   Altmeyer, P ^a   Brockmeyer, N H ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIRETROVIRUS AGENT; CALCITRIOL; DIDANOSINE; ETRETIN; INFLIXIMAB; LAMIVUDINE; LOPINAVIR; METHOTREXATE; PREDNISOLONE; TAZAROTENE; TRIAMCINOLONE ACETONIDE;

ADULT; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LETTER; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; TREATMENT FAILURE; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DERMATOLOGIC AGENTS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

EID: 2342637791     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0007-0963.2004.05885.x     Document Type: Letter

References (13)

1. Wolfer LU, Djemadji-Oudjiel N, Hiletework M et al. HIV-associated psoriasis. Clinical and histological observations in 36 patients. Hautarzt 1998; 49: 197-202.
2. Mallon E, Bunker CB. HIV-associated psoriasis. AIDS Patient Care STDS 2000; 14: 239-46.
3. Breuer-McHam JN, Ledbetter LS, Sarris AH, Duvic M. Cytokine expression patterns distinguish HIV associated skin diseases. Exp Dermatol 2000; 9: 341-50.
4. Craven NM, Jackson CW, Kirby B et al. Cytokine gene polymorphisms in psoriasis. Br J Dermatol 2001; 144: 849-53.
5. Ritchlin C, Haas-Smith SA, Hicks D et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25: 1544-52.
6. Ettehadi P, Greaves MW, Wallach D et al. Elevated tumor necrosis factor-alpha biologic activity in psoriatic lesions. Clin Exp Immunol 1994; 96: 146-51.
7. Bondeson J, Maini RN. Tumor necrosis factor as a therapeutic target in rheumatoid arthritis and other inflammatory diseases: the clinical experience with infliximab (Remicade). Int J Clin Pract 2001; 55: 211-6.
8. O'Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis, a report of 2 cases. Arch Dermatol 2002; 138: 644-8.
9. Ogilvie AL, Antoni C, Dechant C et al. Treatment of psoriatic arthritis with antitumor necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001; 144: 587-9.
10. Aboulfa DM, Bundow D, Wilske K, Ochs I. Etanercept for treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000; 75: 1093-8.
11. Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-26.
12. Behrens GM, Meyer D, Stoll M, Schmidt RE. Immune reconstitution syndromes in human immunodeficiency virus infection following effective antiretroviral therapy. Immunobiology 2000; 201: 186-93.
13. Gaylis N. Infliximab in the treatment of an HIV positive patient with Reiter's syndrome. J Rheumatol 2003; 30: 407-11.